EMA/296721/2024

European Medicines Agency decision

P/0254/2024

of 19 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for ublituximab (Briumvi), (EMEA-002889-PIP02-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0254/2024

of 19 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for ublituximab (Briumvi), (EMEA-002889-PIP02-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0317/2021 issued on 11 August 2021,

Having regard to the application submitted by Neuraxpharm Pharmaceuticals, S.L. on 23 February 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 May 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ublituximab (Briumvi), concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Neuraxpharm Pharmaceuticals, S.L., 69 Avda. Barcelona, 08970 - Sant Joan Despi, Barcelona, Spain.

EMA/PDCO/91765/2024 Corr[1]
Amsterdam, 31 May 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002889-PIP02-20-M01

Scope of the application

Active substance(s):

Ublituximab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of multiple sclerosis

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Neuraxpharm Pharmaceuticals, S.L.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Neuraxpharm Pharmaceuticals, S.L. submitted to the European Medicines Agency on 23 February 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0317/2021 issued on 11 August 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 2 April 2024.

[1] 17 June 2024

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
    - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.
2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of multiple sclerosis

The waiver applies to:

- the paediatric population from birth to less than 10 years of age;
- concentrate for solution for infusion, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of multiple sclerosis

2.1.1. Indication(s) targeted by the PIP

Treatment of relapsing forms of multiple sclerosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	**Study 1** Open-label, uncontrolled trial to evaluate pharmacokinetics, pharmacodynamics, safety and activity of ublituximab in children from 10 years to less than 18 years of age with relapsing forms of multiple sclerosis. **Study 2** Double-blind, double-dummy, randomised, non-inferiority trial to evaluate safety and efficacy of ublituximab compared to fingolimod in children from 10 years to less than 18 years of age with relapsing forms of multiple sclerosis.

Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of multiple sclerosis

Authorised indication(s):

- Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features
  - Invented name(s): Briumvi
  - Authorised pharmaceutical form(s): Concentrate for solution for infusion
  - Authorised route(s) of administration: Intravenous use
  - Authorised via centralised procedure